Randomised controlled trials of iron chelators for the treatment of cardiac siderosis in thalassaemia major
In conditions requiring repeated blood transfusion or where iron metabolism is abnormal, heart failure may result from accumulation of iron in the heart (cardiac siderosis). Death due to heart failure from cardiac iron overload has accounted for considerable early mortality in β-thalassemia major. T...
Saved in:
Main Authors: | Arun John Baksi (Author), Dudley J Pennell (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2014-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
REGIONAL SIDEROSIS: A NEW CHALLENGE FOR IRON CHELATION THERAPY
by: Zvi Ioav Cabantchik, et al.
Published: (2013) -
Non-compliance to iron chelation therapy in patients with transfusion-dependent thalassaemia
by: Allen Shiun Chat Chai, et al.
Published: (2021) -
Deferiprone, an iron chelator, alleviates platelet hyperactivity in patients with β-thalassaemia/HbE
by: Ngan Thi Tran, et al.
Published: (2022) -
Discordant beats - A prospective study of cardiac MRI to assess iron overload in patients with thalassaemia major
by: S. Divya, et al.
Published: (2016) -
Comparison of cardiac dysfunction in thalassemia major patients using deferoxamine or deferiprone as an iron-chelating agent
by: Rosalina Josep, et al.
Published: (2012)